After 20 Years and Hundreds of Compounds, One Drug Keeps Winning: Rapamycin

After 20 Years and Hundreds of Compounds, One Drug Keeps Winning: Rapamycin

A lab mouse gets her standard chow, but there's something extra in it — a fine dust of rapamycin, a compound first isolated from soil bacteria on Easter Island. The National Institute on Aging has been running this experiment, in thousands of mice, across dozens of compounds, for two decades. The verdict is in: rapamycin is the only intervention that reliably extended lifespan across both sexes — 14–26% in females, 9–23% in males — by triggering autophagy, the cellular housekeeping process that clears out damaged proteins before they accumulate into dysfunction.

Out of hundreds of candidates tested since the early 2000s, most flopped or helped only one sex. The compounds that worked shared a common thread: they all tuned metabolism, stress response, immunity, or inflammation. Combination therapies — rapamycin stacked with mitochondria-targeting compounds — are now outperforming single-drug approaches by pulling multiple aging levers at once, hinting at the next generation of protocols.

The translation problem is real: mice live 2–3 years, humans aim for 120, and our tangled genetics, lifestyle variables, and environmental exposures make clean replication nearly impossible. But researchers are already taking low-dose rapamycin off-label, drawn by studies showing measurable metabolic shifts within hours of dosing, not months. Twenty years. Hundreds of compounds. One winner.

Gobble's Take: The most-tested anti-aging drug in history is available off-label right now — the gap between mouse data and your medicine cabinet has never been smaller.

Sources: Healthspan · PMC Rapamycin

Two Cheap Amino Acids Matched Rapamycin's Best Results — and Also Fixed the Mice's Skin

Glycine and N-acetylcysteine (NAC) are not exotic compounds. You can buy both at any supplement shop for under $30. But when researchers combined them into what they're calling GlyNAC and dosed aging mice daily, something striking happened: lifespan stretched by 24%, mitochondrial function recovered, collagen production climbed, and antioxidant defenses surged — all in the same animals.

That 24% figure matches rapamycin's best female-only results, but GlyNAC worked in both sexes and delivered something rapamycin doesn't: structural tissue repair. Better collagen means more resilient skin, stronger connective tissue, and measurable reductions in the oxidative damage that accelerates visible aging. Calcium alpha-ketoglutarate (CaAKG), another compound drawing longevity attention, showed gains too — but only in females. GlyNAC worked across the board.

Human data is early but compelling. Older adults supplementing with GlyNAC in clinical trials reported gains in muscle strength and reductions in fatigue — outcomes that don't show up in a mouse cage but do show up in daily life. Top cosmeceutical researchers are now eyeing both compounds for skin-aging applications, which means the supplement aisle and the dermatology clinic may be converging on the same molecules. Two amino acids beat the king — by repairing what the king merely slows.

Gobble's Take: If rapamycin is the longevity drug everyone talks about, GlyNAC is the one quietly doing the same job for the price of a dinner out.

Source: PMC Cosmeceuticals

Scientists Have Named 12 Reasons You Age — and They're Building a Drug for Each One

In 2005, a group of researchers did something that sounds obvious in retrospect: they sat down and made a list of everything that goes wrong inside cells as we get older. Genomic instability. Telomere shortening. Senescent "zombie" cells that stop dividing but refuse to die, instead leaking inflammatory signals into surrounding tissue. Mitochondria losing efficiency. NAD+ — the molecule that powers cellular energy — dropping by roughly 50% between your 20s and your 50s. They called these the Hallmarks of Aging, and they eventually counted 12.

Twenty years later, geroscience — the field built around treating aging itself rather than individual diseases — has a drug or candidate molecule targeting nearly every one. Rapamycin blocks mTOR, the protein synthesis regulator that goes into overdrive with age. Senolytics like dasatinib and fisetin selectively clear zombie cells before their inflammatory output does broader damage. NAD+ precursors like NMN and NR attempt to recharge the energy deficit. Metformin, the diabetes drug, mimics caloric restriction at the metabolic level. Clinical trials targeting aging hallmarks have tripled since 2010.

No single compound touches all 12, which is why the most serious longevity researchers — and biohackers like Bryan Johnson — are stacking interventions and tracking biomarkers to measure whether the combinations are actually working. Aging, it turns out, isn't one problem. It's 12 overlapping ones, and for the first time in history, most of them have a candidate solution.

Gobble's Take: The era of treating aging like bad luck is over — it's now a list of engineering problems, and the engineers are catching up fast.

Sources: PMC Pharmacological · Healthspan

Bryan Johnson Spends $2M a Year on 11 Numbers — Here's the One That Matters Most

Bryan Johnson, the 47-year-old tech founder running what he calls Project Blueprint, wakes before 5 a.m., swallows 54 pills, and checks a dashboard of 11 biomarkers before most people have had coffee. Of all the numbers on that dashboard, one stands out: his HDL cholesterol sits at 78 mg/dL — roughly double the average American man's level, and well above the 60 mg/dL threshold associated with a 49% reduction in all-cause mortality risk. HDL, the "good" cholesterol, clears arterial plaque, suppresses inflammation, and in emerging research is linked to reduced dementia risk.

Johnson doesn't take statins to hit that number. He gets there through daily HIIT and resistance training, zero added sugar, a tablespoon of olive oil with every meal, and a stack of anti-inflammatory compounds including omega-3s, curcumin, and astaxanthin. His resting heart rate protocol is equally precise: last meal finishes at least four hours before sleep, screens off one hour before bed, conditions calibrated to push RHR as low as possible — because lower resting heart rate during sleep correlates with deeper recovery and longer lifespan across multiple large population studies.

He appears, by most objective measures, physiologically younger than his age. His biological age testing has clocked him younger than his chronological age across multiple markers. Critics frame it as vanity with a spreadsheet. But the biomarkers he tracks — HDL, RHR, VO2 max, inflammatory markers — are the same ones that population epidemiologists use to predict who lives longest. The protocol is extreme; the underlying logic is not.

Gobble's Take: You don't need $2M or 54 pills — you need HDL above 60, and olive oil plus weekly HIIT will get most people there without a single prescription.

Sources: Healthspan · Synchronicity Health

Quick Hits

• Longevity progress is real — so are the scams: Freethink's breakdown of the anti-aging industry warns that legitimate breakthroughs in senolytics and mTOR inhibition are being drowned out by supplement marketing with zero clinical backing — and most consumers can't tell the difference. Freethink Media
• Dr. Rhonda Patrick on why Zone 2 cardio may be the single highest-ROI longevity intervention: Patrick's latest deep-dive argues that consistent low-intensity aerobic training outperforms most supplements at preserving mitochondrial health and cognitive function into old age. Substack

In Case You Missed It

Yesterday's top stories:

• Rapamycin Matches Calorie Restriction — and Starts Working in Hours, Not Months
• The Man Who Trains Tour de France Champions Says the Longevity Industry Is Selling You Anxiety Relief
• NAD+ Drops 50% by Age 50 — Here's the Cheapest Way to Push Back
• A Strawberry Compound Is Clearing Zombie Cells as Effectively as Drugs That Cost Thousands